Drug intelligence / Profile preview

LEAPS

Development stage: Preclinical
Lead developer: CEL-SCI
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Mucosal

Overview

LEAPS is an early-stage technology developed by CEL-SCI Corporation, primarily known as a rheumatoid arthritis vaccine candidate. It is being developed for autoimmune and infectious diseases, specifically targeting the unmet needs of rheumatoid arthritis patients who do not respond to anti-TNF therapies. The National Institutes of Health (NIH) has supported its development through a Phase II SBIR/STTR grant and selected it for their Commercialization Accelerator Program to facilitate its progression from preclinical stages to clinical studies and commercialization.

Beyond the preview

Go deeper on LEAPS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEAPS.

Explore the full profile